Jeffrey Bluestone brings his startup haul to $400M+, joining forces with Regeneron on cell therapies
These days, when Jeffrey Bluestone gets together with his contemporaries in science, the conversation often turns to retirement plans.
But a little more than three years ago, Bluestone reached a momentous turning point in his career, exiting a prestigious post at UCSF, where he had spent decades in the scientific pursuit of new therapies. And it had nothing to do with retirement anytime in the near future.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.